FDA seeks more safety data on Byetta from Lilly, Amylin

12/23/2009 | Bloomberg

The FDA asked Eli Lilly and Co. and Amylin Pharmaceuticals to conduct more safety studies on Byetta in light of reports linking the diabetes drug to pancreatitis. The companies, which co-market the drug, said additional studies are under way and so far have shown no heightened risk of pancreatitis in patients using Byetta.

View Full Article in:

Bloomberg

Published in Brief:

SmartBrief Job Listings for Health Care

Job Title Company Location
Employment Counsel
Gilead
Foster City, CA
Junior to Mid-Level FDA Associate
Morgan Lewis
Washington, DC
Global Counsel - Advertising and Promotions
Mylan Inc.
Washington, DC
Associate Director, Compliance & Ethics, US Operations Ops II
Bristol-Myers Squibb
Plainsboro, NJ
Senior Associate, Health Economics - Heart Valve Therapy
Edwards Lifesciences
Irvine, CA